Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer

Adv Drug Deliv Rev. 2022 Jul:186:114340. doi: 10.1016/j.addr.2022.114340. Epub 2022 May 13.

Abstract

Research on bacterial membrane vesicles (BMVs) is an emerging topic, and the goal is to address whether BMVs can bring translational tools to improve current therapies. In this review, we provided the updated studies on BMVs including their production, their types, and therapeutic regimens for treating infectious diseases and cancers. We described several platforms of BMVs, such as outer membrane vesicles (OMVs), inner membrane vesicles (IMVs) and double membrane vesicles (DMVs), and those structures were produced from Gram-negative or Gram-positive bacteria. We also discussed how to engineer and formulate new and novel BMVs using chemical, physical, and genetic methods. For therapies, we analyzed current methods for loading drugs in BMVs and discussed their limitations. Finally, we reviewed several therapeutic platforms of BMVs that have been exploited in improving the treatments of infectious diseases and cancers. Although BMVs offer the promising biomedical applications, it is needed to develop rigorous approaches and methods to generate reproducible and scalable drug delivery systems for translation.

Keywords: Anti-cancer therapy; Anti-infection therapy; Bacterial membrane vesicles; Outer membrane vesicles.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Bacteria
  • Cell Membrane
  • Communicable Diseases* / drug therapy
  • Drug Delivery Systems
  • Humans
  • Neoplasms* / drug therapy